TNFRSF17 and plasma cell myeloma: Both of the tandem dual-specific CAR T cells had higher in vitro cytotoxicity compared to monospecific anti-BCMA and anti-TACI L-H CAR T cells against wildtype multiple myeloma cell lines MM1S and RPMI-8226 (Fig. 6a, b).